6. Segment Information

We are currently operating as a single operating segment.

Geographical information

In 2024 and 2025, our continuing operations were mainly located in Belgium, France, the Netherlands, Switzerland and the United States. The revenues from our collaboration partner Gilead represented 97% of our total net revenues from continuing operations in 2025 (87% in 2024). The main part of the remaining 3% of the net revenues in 2025 (remaining 13% in 2024) consisted of supply revenues of the Jyseleca® product to Alfasigma (Italy). The revenues in the country of domicile of Galapagos NV (Belgium) are not material.

Following table summarizes our net revenues by destination of customer:

On December 31, 2025, we held €81.5 million (€357.8 million in 2024) of property, plant and equipment, intangible assets and goodwill distributed as follows: